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Abstract
Background: Despite significant protection in preclinical studies, cellulose sulfate (CS) failed to protect women against HIV-
1/2 and was associated with a trend toward increased HIV-1 acquisition in one of the clinical trials. These results highlight
the need for preclinical tests more predictive of clinical outcomes. The objective of this study was to test coded vaginal gels,
including CS, in murine models of safety and efficacy to determine the models’ utility for evaluating future products.
Methods: Four coded formulations, including 6% CS, 2% PRO 2000 and two placebo gels, were administered intravaginally
to medroxyprogesterone-treated mice and their ability to prevent genital herpes (efficacy) or to alter the susceptibility to
low dose HSV challenge (safety) was determined. Nonoyxnol-9 served as a positive toxicity control.
Results: CS and PRO 2000 significantly protected mice from genital herpes following infection with a laboratory or clinical
isolate of HSV-2 introduced in buffer (p,0.001). However, protection was reduced when virus was introduced in seminal
plasma. Moreover, mice were significantly more susceptible to infection with low doses of HSV-2 when challenged 12 h
after the 7th daily dose of CS or nonoxynol-9 (p,0.05). The increased susceptibility was associated with alterations in
epithelial architecture.
Conclusions: CS prevented genital herpes when present at the time of viral challenge, but increased the rate of infection
when gel was applied daily for 7 days with a vaginal wash prior to viral inoculation. The findings presumably reflect altered
epithelial architecture, which may have contributed to the trend towards increased HIV observed clinically.
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Introduction
Clinical trials of topical pre-exposure prophylaxis (PrEP) (also
referred to as microbicides) for HIV prevention have yielded
uniformly disappointing results, with the exception of the recent
tenofovir gel trial [1]. Particularly concerning were the observa-
tions that some products not only failed to protect against
infection, but were associated with higher rates of HIV acquisition
in placebo-controlled efficacy trials [2–4]. While an increased risk
of HIV following frequent exposure to a surfactant such as
nonoxynol-9 (N-9) is not totally surprising, the observation in one
of the trials that cellulose sulfate (CS) was associated with a trend
towards higher rates of HIV infection compared to placebo (25
versus 16 new infections; relative risk=1.61, p=0.13) was
unanticipated [2]. These results underscore the need to develop
and validate more predictive preclinical biomarkers of safety and
efficacy. This need will become even greater as partially protective
topical and oral products are advanced into the clinic, rendering it
more difficult and costly to conduct trials.
For a preclinical model to be valuable, it must be reflective of
human disease and the results obtained with previously tested
interventions should be consistent with the findings in clinical
studies. Developing models of HIV transmission is particularly
difficult because many of the key parameters are either unknown
(e.g. inoculum dose) or difficult to simulate (e.g. effects of sex and
semen on infection) [5]. Non-human primate (NHP) models
provide important insights regarding HIV pathogenesis and
potential efficacy of oral or topical PrEP [6], but so far have not
proven to be consistently predictive of clinical outcomes [7]. For
example, in a study conducted in rhesus macaques, none of the six
animals treated intravaginally with 6% CS gel became infected
compared to five of six macaques treated with hydroxyethylcellu-
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27675lose (HEC) placebo gel [8]. Similarly, Carraguard (a mixture of
lambda and kappa-Carrageenan), which failed to prevent HIV
infection in clinical trials [9], blocked vaginal transmission of RT-
SHIV in macaque studies [10].
We previously published results with two potentially synergistic
preclinical safety models: (i) a dual chamber culture model, which
examines the impact products have on epithelial cell integrity and
mediators of innate immunity [11]; and (ii) a murine model, which
evaluates the effects of formulated gels on susceptibility to genital
HSV-2 infection [12,13]. We hypothesize that increased suscep-
tiblity to HSV-2 in the murine model, whch may reflect changes in
mucosal integrity and immune environment, will predict increased
susceptibility to HIV infection. We applied these models to
evaluate N-9, PRO 2000 and tenofovir [11–13]. The active phar-
maceutical ingredients (APIs) were studied in the dual chamber
model and the formulated gels in the mouse. Results obtained
indicated that these models would have correctly predicted that
0.5% PRO 2000 and 1% tenofovir gel were safe.
We also tested CS as API in the dual chamber model [11] and
found that single and repeated exposures to CS (100 mg/ml)
triggered a decrease in transepithelial electrical resistance (TER)
and an increase in HIV migration across the epithelial barrier,
which resulted in infection of T cells cultured in the lower
chamber. Building on this background, the current study was
designed to test four blind-coded formulated gels (one of which
was 6% CS) in murine models of efficacy and safety.
Results
Protection against genital herpes
Medroxyprogesterone acetate (MPA)-treated mice received a
single application of each gel (or no treatment) and were then
challenged 15 min later with ,10
5 pfu/mouse of HSV-2(G)
delivered in PBS and monitored for signs of disease. This dose is
lethal in 60–90% of mice. Two of the products, CS 6% gel and
PRO 2000 2% gel, provided significant protection, keeping 90%
of the animals alive 14 days post-inoculation, whereas the others (a
placebo gel matched to the CS formulation and HEC, the
universal placebo gel) had little or no protective effect (Fig. 1A,
p,0.05). Notably, N-9 failed to protect against genital herpes. CS
and PRO 2000 also provided significant protection relative to
HEC against a clinical HSV-2 isolate (p=0.0013 and p,0.0001,
respectively) (Fig. 1B).
To further evaluate the active gels under conditions that more
closely reflect what happens clinically, we also tested the activity
when virus was introduced in seminal plasma. Delivering virus in
Figure 1. Cellulose sulfate and PRO 2000 gels protect mice from genital herpes, but the response is modulated when virus is
introduced in seminal plasma. (A). Survival curves for mice pretreated with a single dose of each blinded gel or no gel (untreated) and challenged
with an LD90 of HSV-29G) diluted in PBS. Survival curves for mice pretreated with a single dose of DE-021 (HEC), DE-018 (CS) or DE-020 (PRO 2000)
and challenged with an LD90 of HSV-2(4674) diluted in PBS (B) or pooled human seminal plasma (C). Data were obtained from 2 independent
experiments (10 mice per group). The asterisk denotes significant protection relative to HEC-treated mice (p,0.001 for virus introduced in PBS and
p=0.015 for virus introduced in seminal plasma).
doi:10.1371/journal.pone.0027675.g001
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that killed 90% of HEC treated mice (LD90) when virus was
introduced in PBS (Fig. 1B) was reduced to an LD60 (Fig. 1C).
Under these experimental conditions, CS 6% gel no longer
provided significant protection (p=0.36), whereas the activity of
PRO 2000 2% gel, though reduced, remained significant
(p=0.015). These findings are consistent with in vitro studies in
which seminal plasma significantly reduced the antiviral activity of
CS and PRO 2000 API by competitively blocking the binding of
the polyanionic drugs to the viral envelope [14].
Increased susceptibility to HSV-2 following exposure to
gels
To determine if any of the blinded gel products increased the
susceptibility to low dose challenge with HSV-2, mice were treated
once daily for seven consecutive days and then 12 h after the last
gel application, vaginal washes were collected to remove any
residual drug and subsequently assayed for anti-HSV activity
(Fig. 2). There was sufficient drug within vaginal washes from mice
that had received CS 6% gel, but not PRO 2000 2% gel, to inhibit
HSV-2 infection in a plaque assay. This is in agreement with the
bioadhesive properties of CS gel and its observed prolonged time
of vaginal residence [15].
The mice were then challenged with serial dilutions of virus
representing an LD10, LD40, and LD90 (doses at which 10, 40
and 90% of the population is expected to succumb to disease,
respectively). Half of the mice pretreated with CS 6% gel
succumbed to infection following challenge with an ,LD10
compared to only 10% of HEC-treated mice (p=0.05) (Fig. 3,
upper panel). Similarly, 14 of 20 mice (70%) pretreated with CS
succumbed to challenge with an ,LD40 compared to 7/20 (35%)
of mice treated with HEC (p=0.03) (middle panel). Mice treated
with PRO 2000 2% gel exhibited a non-significant trend toward
increased susceptibility following challenge with an LD40
(p=0.08), but no increase in susceptibility was observed following
challenge with an LD10. There were no differences in survival
curves between products following challenge with an LD90 (lower
panel) and the majority of animals succumbed to disease with this
high inoculum. N-9 significantly increased the susceptibility to
genital disease after challenge with an LD40.
Increased susceptibility reflects changes in epithelial
architecture
To determine if changes in the epithelium contributed to the
increased susceptibility to HSV-2 in the mouse as had been
observed in the dual chamber culture model [11], genital tract
tissue was excised after seven daily doses of gel and evaluated by
confocal microscopy. Images of the lower genital tract represen-
tative of results obtained from three mice per group are shown
(Fig. 4A). The junctional proteins (zona occludens (ZO-1), green
and desmoglein, red) were not readily detected in the 3-D images
of HEC-treated tissue, reflecting compact epithelium with intact
tight junctions. Treatment with N-9 led to thinning of the
epithelium, loss of plasma membrane staining (magenta) and
increased detection of ZO-1. Exposure to CS resulted in modest
thinning of the epithelium, a reduction in plasma membrane
staining, and increased visualization of desmoglein. In addition, in
the xz images (lower panels), ZO-1 appeared to be mispolarized
towards the basal side of the tissue and to be more dispersed
compared to HEC-treated tissue. There was some loss of plasma
membrane staining with a concomitant increase in the visualiza-
tion of desmoglein in PRO 2000 treated tissue.
To address whether the changes in epithelial architecture
facilitated the penetration of HSV into the epithelium, mice that
had received seven daily doses of gel were challenged with HSV-2
and four hours after viral challenge, the animals were sacrificed
and the presence of viral capsids was assessed by immunostaining
with an antibody to the HSV capsid protein, VP16. The tissue was
also stained with phalloidin (which stains actin) and DAPI to
delineate the cytoplasm and nuclei, respectively. Z-stack images
were obtained starting from the first detected fluorescent signal
and continued in 0.5-micron increments and pixel intensities on
axial images were quantified (Fig. 4B). Viral capsids extended
more than 50 microns into the tissue following exposure to N-9 or
CS and both products led to an increase in viral capsids detected
within the tissue as evidenced by a significant increase in the area
under the curve compared to tissue extracted from mice treated
with either placebo gel or mice treated with PRO 2000 (Fig. 4B
and 4C) (p,0.001, ANOVA).
Exposure to gels triggers release of inflammatory
cytokines and chemokines
Tight junctions are regulated in part by inflammatory cytokines
such as IFN-c, TNF-a, and IL-1b, which have been shown to
trigger intestinal epithelial barrier dysfunction [16–18]. To
determine whether the disruption in the epithelium was associated
with increases in any of these cytokines, vaginal washes were
analyzed for cytokine concentrations. Compared to mice treated
with either placebo gel, N-9 induced a significant increase in all
three inflammatory cytokines after seven doses, although no
increases were observed after three daily doses. CS also induced
significant increases in IFN-c after the third gel application and
TNF-a and IL-1b after seven daily doses. PRO 2000 induced only
a transient increase in TNF-a after three doses (Fig. 5A).
Microbicides may also promote inflammation and recruitment
of HIV target cells into the genital tract by triggering the release of
chemokines. To explore this notion, vaginal washes were also
analyzed for the presence of CXCL1 (KC), CXCL2 (MIP-2), and
RANTES. Vaginal washes collected after three doses from mice
treated with PRO 2000) had significantly more CXCL1 and
RANTES and washes from mice treated with N-9 had higher
Figure 2. Vaginal washes from mice treated with cellulose
sulfate 6% gel inhibit HSV-2 plaque formation. To remove any
residual drug within the vaginal lumen prior to HSV-2 challenge in the
safety studies, vaginal washes were obtained with 100 ml of saline. The
vaginal washes were tested in a viral plaque assay. Results are means
(SEM) from 2 independent experiments with pooled washes from 5
mice each; the asterisk denotes p,0.05.
doi:10.1371/journal.pone.0027675.g002
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CXCL-1 in response to CS after three doses.
Discussion
Precisely how HIV viral particles and/or infected cells traverse
the epithelium lining the lower female reproductive tract to reach
lamina propria and submucosal immune target cells and establish
an infection is not fully understood. HIV transmission is increased
when the integrity of the epithelium is impaired, as in the setting of
ulcerations, inflammation or cervical ectopy [19]. Cervical ectopy,
the presence of single-layered columnar epithelium outside the
cervical os, an area normally lined by multilayered squamous
epithelium, is more frequently present in adolescents and may be
increased with hormonal contraception, pregnancy and cervical
infections [20]. The link between HIV acquisition and conditions
that disrupt the epithelial barrier highlights the need to develop
and incorporate measurements of epithelial integrity in the
assessment of topical product safety. However, there are no
standardized validated methods to perform this evaluation.
Studies in NHP and early clinical safety studies have
traditionally used colposcopy as a primary outcome measure.
However, this approach has not always proven to be predictive of
safety. For example, a standardized NHP model that incorporated
colposcopy as a major indicator of safety concluded that 24
different products including several different formulations of N-9,
1% C31G, and 6% CS gel were safe [21]. Similarly, phase I
clinical studies, which relied on colposcopy as primary endpoints,
also failed to detect any potential safety concerns with these
formulations [22–24]. In spite of their preclinically demonstrated
antiviral activity, each of these products failed to protect women
from HIV infection and was associated with at least a trend
Figure 3. Increased susceptibility to HSV-2 following seven daily gel applications. Mice were challenged with ,10
3,1 0
4 or 10
5 pfu/mouse
of HSV-2(4674) (upper, middle and bottom panels, respectively), representing an LD10, LD40, and LD90 12 h after receiving the seventh daily dose of
N-9 or coded gel products and after vaginal washing. Animals were observed daily for signs and symptoms of disease. Mice developing severe genital
or neurological disease were euthanized. Results show percent survival pooled from at least 2 independent experiments (n=20 mice/group). The
asterisks denote p,0.05.
doi:10.1371/journal.pone.0027675.g003
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ness trials [2–4,25].
More recently, optical coherence tomography (OCT) has been
proposed as an alternative non-invasive method to assess the
epithelium and has been evaluated in sheep and NHP studies with
N-9 and benzalkonium chloride [26,27]. OCT detected toxicities
with these two surfactant products, but additional studies with
non-surfactant compounds are needed to determine the predictive
value of this methodology.
Results of the current study with coded gels suggest that a
simple, relatively inexpensive murine model may provide a
predictive measure of epithelial barrier integrity. The findings
obtained parallel those in the dual-chamber cell culture model
[11] and, most importantly, are consistent with the clinical
effectiveness outcomes of three of the coded samples, 6% CS, 2%
PRO 2000 and HEC (note that the placebo gel matched to CS
was not evaluated in clinical trials). In this study, repeated
intravaginal exposure of mice to 6% CS (and N-9) induced changes
in the epithelial architecture that led to increased permeation of
HSV viral particles through the epithelium. We speculate that a
similar mechanism may have contributed to the trend towards
increased HIV acquisition observed in one of the two CS trials [2].
In addition to the increased susceptibility to HSV, a modest but
significant increase in IFN-c, TNF-a, and IL-1b was detected in
vaginalwashes,whichmayhavecontributed totheepithelialbarrier
dysfunction. Phase I clinical studies, however, did not report an
increase in cervicovaginal cytokines or chemokines upon repeated
exposure to CS gel [22].
Consistent with studies performed with open-labeled PRO 2000
gel [13], modest changes in the epithelium and an increase in
chemokines in vaginal washes, which were associated with a non-
significant increase in the susceptibility to HSV, were induced by
this product in the present study. These responses may have
contributed to the lack of clinical efficacy of PRO 2000 gel [28].
Figure 4. N-9 and cellulose sulfate causes disruption of the epithelium. Mice were treated daily for seven days with microbicides and twelve
hours after the final application, the mice were sacrificed and the entire vaginal canal up to the uterine bifurcation was excised. The tissue was then
fixed and stained with EZ-Link Sulfo-NHS-Biotin to detect the apical surface (magenta) and DAPI to detect nuclei (blue), ZO-1 (green) and desmoglein
(DSG, red) and viewed by confocal microscopy. Representative 3-dimensionsal (upper panel) and xz (lower panels) images are shown (A). Images
were taken from at least 3 animals per treatment group and at least 6 independent randomly selected images were acquired per animal. To assess
whether disruption of the epithelial barrier promoted HSV migration through the tissue, mice were inoculated with HSV-2 12 hours after the seventh
daily gel application and were then sacrificed four hours after infection. Tissues were stained for viral capsids with a mAb to VP16; phalloidin, which
stains actin and was used to delineate the cytoplasm; and DAPI to identify nuclei. Individual Z slices were analyzed and intensity density of the
fluorescence quantified. The results are means obtained from 8 independent randomly selected images (2 images per genital tract sample) (B) and
the cumulative area under the curve is shown in C; asterisks indicate a significant increase in the area under the curve (p,0.001, ANOVA).
doi:10.1371/journal.pone.0027675.g004
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to viral challenge might unmask additional toxicities and requires
further study.
Notably, mice are pretreated with MPA, which hormonally
synchronizes the animals, thins the epithelium, and up-regulates
the expression of the HSV co-receptor, nectin-1 [29], resulting in
greater susceptibility to HSV infection. The increased susceptibil-
ity to genital herpes following MPA treatment parallels clinical
findings of increased HIV risk in women treated with Depo-
ProveraH [30]. Thinning of the epithelium likely exacerbates the
deleterious effects of compounds on epithelial integrity.
There are several limitations of the model that underscore the
need to evaluate products in multiple systems to assess safety. For
example, the mouse model does not provide an opportunity to
evaluate the impact on vaginal flora, which also plays a key role in
host defense. Recent data suggest that CS may modify epithelial-
microflora interactions leading to disturbed vaginal microbial
communities [31]. Another limitation is the species differences in
the expression and regulation of soluble mucosal immune
mediators such as defensins, which may impact the susceptibility
to HIV and HSV infection [32–35]. Most importantly, the mouse
is not susceptible to HIV infection rendering it necessary to rely on
susceptibility to HSV as a surrogate. Humanized mouse models
have been developed, but the extent to which these provide models
of product safety is not yet known [36].
While the primary objective of these studies was to evaluate
safety, we also assessed the efficacy of the coded samples when
mice were challenged with a high dose of HSV-2 diluted either in
PBS or in human seminal plasma. Both 6% CS and 2% PRO
2000 significantly protected mice from disease when either a
laboratory strain or clinical isolate was introduced in PBS.
However, the protective effect was reduced when virus was
diluted directly into human seminal plasma. These findings are
consistent with a recently completed postcoital clinical study with
PRO 2000 [37] and likely reflect competition between seminal
plasma proteins and polyanionic drugs for binding sites on the
viral envelope [14]. We speculate that the reduced antiviral
activity of CS and PRO 2000 in the presence of semen, combined
with impaired epithelial architecture, overcame the anti-HIV
efficacy of these products.
Results of the current studies indicate that these simple and
relatively inexpensive murine models should be considered early in
the preclinical development of of next generation candidate topical
PrEP. While the efficacy of HIV-specific products cannot be tested
in mice, the findings support the need to evaluate efficacy in
alternative in vitro or animal models where HIV is introduced in
semen prior to initiating clinical trials. Validated biomarkers of
efficacy and safety will become of even greater importance as we
strive to improve upon the encouraging results obtained with
topical tenofovir.
Materials and Methods
Cells and viruses
CaSki (human cervical) and Vero (monkey kidney) epithelial cell
lines were obtained from the American Tissue Culture Collection
(ATCC); human keratinocytes (HaCAT) were obtained from
David Johnson (Oregon Health & Sciences University, Portland,
OR). All cells were grown and maintained in Dulbecco’s modified
Eagles medium (DMEM) supplemented with 10% fetal bovine
serum (FBS). HSV-2(G), originally isolated from a genital lesion
[38], was grown on Vero cells and HSV-2(4674), a clinical isolate
obtained from the clinical virology laboratory at Montefiore
Hospital, was propagated on HaCAT cells.
Figure 5. Changes in cytokines and chemokines in response to microbicides. The levels of chemokines and cytokines were measured in
vaginal washes pooled from 5 mice by BioLuminex. Results are presented as mean 6 SE values from six different pools (5 mice per pool) for washes
obtained after three daily doses and from at least three pools for washes obtained after seven daily doses. The asterisks denote p,0.05 relative to
HEC-treated mice.
doi:10.1371/journal.pone.0027675.g005
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Four coded gels were provided by CONRAD (DE8-018, DE8-
019, DE8-020, and DE8-021) and upon locking the data, were
identified as 6% CS, a placebo-matched control, 2% PRO 2000,
and HEC-based universal placebo, respectively. Encare, which
contains 4% N-9 (Blairex Laboratories, Inc., Columbus, IN), was
included as an unblinded positive control for toxicity.
Murine model
Studies were conducted with approval of the Albert Einstein
College of Medicine Institutional Animal Care and Use Commit-
tee. To assess whether gels prevented genital herpes (efficacy),
female BALB/c mice (7–10 weeks) were pretreated subcutaneously
with 2.5 mg of MPA (Sicor Pharmaceuticals, Irvine, CA, USA)
and five days later were inoculated intravaginally with 20 mlo f
each blinded gel or N-9. Fifteen minutes later, mice were
challenged with 30 ml of virus (equivalent to ,10
5 plaque forming
units (pfu)). The virus was diluted either in phosphate buffered
saline (PBS) or in pooled human seminal plasma (Lee BioSolu-
tions, St Louis, MO). The mice were evaluated for 14 days for
evidence of erythema, edema, genital ulcers, hair loss around the
perineum, urinary or fecal retention and hind-limb paralysis and
were euthanized if symptoms of severe genital tract or neurologic
disease developed [39].
To assess whether exposure to gel increased the susceptibility to
infection, 40 ml of each gel was delivered intravaginally daily for
seven days to MPA-treated mice. Approximately 12 hours after
the seventh application, vaginal fluid was collected by washing
with 100 ml of normal saline and then groups of five mice were
inoculated with HSV-2 equivalent to approximately 10
3,1 0
4 and
10
5 pfu per mouse. Additional mice were treated daily for 7 days
with each gel (first dose delivered on Day 0) and vaginal washes
(100 ml of normal saline) were collected for detection of cytokines
and chemokines from groups of five mice on days 0, 3 (prior to
vaginal dosing) and on day 7. Mice from each treatment group
(n=3–5) were sacrificed at different times and genital tract tissue
excised and processed for confocal microscopy.
Plaque assays
CaSki cells were grown in 24-well plates and were then
inoculated with 10
3 and 10
4 pfu/ml of HSV-2(G) that had been
mixed 1:1 with vaginal washes pooled from 5 mice per treatment
arm. After incubation for 1 h, the cells were washed and overlaid
with methylcellulose (0.5% methylcellulose dissolved in medium
199 supplemented with 1% heat-inactivated FBS). Viral plaques
were counted by a ‘‘black-plaque’’ immunoassay 48 h after
infection using a rabbit polyclonal anti-HSV antibody (1:500;
Genway Biotech, Inc., San Diego, CA) and a goat anti-rabbit IgG
horseradish peroxidase conjugate (1:500; Bio-Rad Laboratories,
Hercules, CA) [40].
Confocal microscopy
Genital tract tissue was excised and processed using previously
detailed methods [13]. The plasma membranes were stained with
EZ-link sulfosuccinimidobiotin reagent (EZ-link, 1:1,000; Pierce,
Rockford, IL, USA), which reacts with primary amines on cell
surface proteins. Non-specific antibody binding sites were blocked
by overnight incubation at 4uC with PBS containing 10% goat
serum and 1% bovine serum albumin. Subsequently, bound EZ-
link was detected by treatment with streptavidin conjugated to
Alexa Fluor 647 (1:1,000); tight junctions were detected with
rabbit anti-zona occludens protein 1 (ZO-1; 1:500) and Alexa
Fluor 488-conjugated secondary antibody (1:1,000), and adherens
junctions were detected with mouse anti-desmoglein-1 (1:500) and
Alexa Fluor 555-conjugated secondary antibody (1:1,000) (all
antibodies from Invitrogen, Carlsbad, CA, USA). Nuclei were
detected by staining with 49,69-diamidino-2-phenylindole nucleic
acid stain (DAPI; Molecular Probes, Inc.; 1:2000 dilution; Eugene,
OR).
To examine the extent of HSV penetration through the tissue,
tissue was excised four hours after HSV challenge and incubated
with mouse anti-viral capsid protein,VP16 (1:500; Santa Cruz
Biotechnology, Santa Cruz, CA) and Alexa Fluor-488 secondary
antibody. F-actin was stained with Alexa Fluor 555 Phalloidin
(Invitrogen; 1:40; Carlsbad, CA) and nuclei were stained with
DAPI. The tissue was mounted on glass slides using ProLong Gold
Antifade reagent (Invitrogen) and images were obtained on a Leica
SP5 AOBS confocal microscope (63x objective; three-dimensional
(3-D) composite images were created from Z-stack images
(Volocity Software). Individual Z slices were analyzed using Image
J software to quantify the fluorescence.
Cytokine and chemokine analyses
Protease inhibitors (Complete Protease Inhibitor Cocktail;
Roche Applied Science, Indianapolis, IN) were added to each
pooled vaginal wash sample before centrifugation at 210 g for
10 min at 4uC. The supernatants were stored at 280uC and
assayed for cytokines and chemokines using the Fluorokine
MultiAnalyte profiling system (R&D Systems, Minneapolis, MN,
USA), measured with a Bioluminex 100 system (Bioluminex,
Austin, TX) and analyzed with StarStation (version 2.0; Applied
Cytometry Systems, Sheffield, UK).
Statistical analyses
Kaplan-Meier survival curves were assessed by log-rank test and
cytokines and chemokines were analyzed by one-way analysis of
variance (ANOVA) using Prism software (version 5; GraphPad).
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